IP Library › Granted Patent US 12,410,480
Granted Patent B2
US 12,410,480 · App. 18/163,138 · Granted Sep 9, 2025

Methods and systems for detecting colorectal cancer via nucleic acid methylation analysis

Inventors: John St. John (Brisbane, CA); Steven Kothen-Hill (Millbrae, CA); Rui Yang (Burlingame, CA); Adam Drake (Pacifica, CA)
Assignee: Freenome Holdings, Inc.
C12Q1/6886G16B20/10G16B40/20C12Q1/6806C12Q1/6869C12Q2600/154
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,410,480
App. No.
18/163,138
Granted
Sep 9, 2025
Kind
B2
Abstract

The present disclosure provides methods and systems for screening or detecting a colorectal cancer or following colorectal disease progression that may be applied to cell-free nucleic acids such as cell-free DNA. The method may use detection of methylation signals within a single sequencing read in identified genomic regions as input features to train a machine learning model and generate a classifier useful for stratifying populations of individuals. The method may comprise extracting DNA from a cell-free sample obtained from a subject, converting the DNA for methylation sequencing, generating sequencing reads, and detecting colon proliferative cell disorder-associated signals in the sequencing information and training a machine learning model to provide a discriminator capable of distinguishing groups in a subject population such as healthy, cancer or distinguishing disease subtype or stage. The method may be used for, e.g., predicting, prognosticating, and/or monitoring response to treatment, tumor load, relapse, or colorectal cancer development.

Claims (127)

1. A method of treating a colorectal cancer in a subject, the method comprising:

(a) subjecting a cell-free deoxyribonucleic acid (cfDNA) sample obtained or derived from the subject to conditions sufficient to convert unmethylated cytosines to uracils in nucleic acid molecules of the cfDNA sample, thereby generating a plurality of converted nucleic acid molecules;

(b) contacting the plurality of converted nucleic acid molecules with nucleic acid probes complementary to a pre-determined methylation signature panel of at least two genomic regions selected from the group consisting of

ITGA4, chr2: 181457004-181457950;

EMBP1, chr1: 121519076-121519744;

TMEM163, chr2: 134718243-134719428;

SFMBT2, chr10: 7408046-7408953;

ELMO1, chr7: 37448612-37449471;

ZNF543, chr19: 57320164-57320845;

SFMBT2, chr10: 7410025-7411008;

CHST10, chr2: 100417269-100417795;

ELMO1, chr7: 37447852-37448217;

CCNA1, chr13: 36431498-36432414;

BEND4, chr4: 42150707-42153216;

KRBA1, chr7: 149714695-149715338;

S1PR1, chr1: 101236505-101237190;

PPP1R16B, chr20: 38805341-38807221;

IKZF1, chr7: 50304053-50304994;

LONRF2, chr2: 100322082-100322599;

ZFP82, chr19: 36418330-36418931;

FLT3, chr13: 28099881-28100943;

FBN1, chr15: 48644595-48646444; and

FLI1, chr11: 128693042-128694372,

to enrich for sequences corresponding to the pre-determined methylation signature panel;

(c) determining a threshold value for each of the at least two genomic regions, wherein the threshold value is indicative of a number of methylated CpG sites in each of the at least two genomic regions;

(d) comparing the number of methylated CpG sites in each of the at least two genomic regions to the threshold value;

(e) determining that the number of methylated CpG sites in each of the at least two genomic regions is above the threshold value, thereby identifying the subject as having the colorectal cancer; and

(f) responsive to the determining in (e), administering a therapeutic intervention to the subject to treat the colorectal cancer in the subject, wherein the therapeutic intervention comprises a chemotherapy, a radiotherapy, an immunotherapy, or a surgery.

2. The method of claim 1 , further comprising amplifying the plurality of converted, enriched nucleic acid molecules.

3. The method of claim 2 , wherein the amplifying comprises polymerase chain reaction (PCR).

4. The method of claim 1 , further comprising sequencing the plurality of converted, enriched nucleic acid molecules at a depth of greater than 1000×, thereby generating nucleic acid sequences.

5. The method of claim 4 , further comprising aligning the nucleic acid sequences to a reference human genome, thereby generating a methylation profile of the subject, wherein the reference human genome is hg18 or hg19.

6. The method of claim 1 , wherein the pre-determined methylation signature panel comprises three or more genomic regions selected from the group consisting of

ITGA4, chr2: 181457004-181457950;

EMBP1, chr1: 121519076-121519744;

TMEM163, chr2: 134718243-134719428;

SFMBT2, chr10: 7408046-7408953;

ELMO1, chr7: 37448612-37449471;

ZNF543, chr19: 57320164-57320845;

SFMBT2, chr10: 7410025-7411008;

CHST10, chr2: 100417269-100417795;

ELMO1, chr7: 37447852-37448217;

CCNA1, chr13: 36431498-36432414;

BEND4, chr4: 42150707-42153216;

KRBA1, chr7: 149714695-149715338;

S1PR1, chr1: 101236505-101237190;

PPP1R16B, chr20: 38805341-38807221;

IKZF1, chr7: 50304053-50304994;

LONRF2, chr2: 100322082-100322599;

ZFP82, chr19: 36418330-36418931;

FLT3, chr13: 28099881-28100943;

FBN1, chr15: 48644595-48646444; and

FLI1, chr11: 128693042-128694372.

7. The method of claim 1 , wherein the pre-determined methylation signature panel comprises six or more genomic regions selected from the group consisting of

ITGA4, chr2: 181457004-181457950;

EMBP1, chr1: 121519076-121519744;

TMEM163, chr2: 134718243-134719428;

SFMBT2, chr10: 7408046-7408953;

ELMO1, chr7: 37448612-37449471;

ZNF543, chr19: 57320164-57320845;

SFMBT2, chr10: 7410025-7411008;

CHST10, chr2: 100417269-100417795;

ELMO1, chr7: 37447852-37448217;

CCNA1, chr13: 36431498-36432414;

BEND4, chr4: 42150707-42153216;

KRBA1, chr7: 149714695-149715338;

S1PR1, chr1: 101236505-101237190;

PPP1R16B, chr20: 38805341-38807221;

IKZF1, chr7: 50304053-50304994;

LONRF2, chr2: 100322082-100322599;

ZFP82, chr19: 36418330-36418931;

FLT3, chr13: 28099881-28100943;

FBN1, chr15: 48644595-48646444; and

FLI1, chr11: 128693042-128694372.

8. The method of claim 1 , wherein the pre-determined methylation signature panel comprises nine or more genomic regions selected from the group consisting of

ITGA4, chr2: 181457004-181457950;

EMBP1, chr1: 121519076-121519744;

TMEM163, chr2: 134718243-134719428;

SFMBT2, chr10: 7408046-7408953;

ELMO1, chr7: 37448612-37449471;

ZNF543, chr19: 57320164-57320845;

SFMBT2, chr10: 7410025-7411008;

CHST10, chr2: 100417269-100417795;

ELMO1, chr7: 37447852-37448217;

CCNA1, chr13: 36431498-36432414;

BEND4, chr4: 42150707-42153216;

KRBA1, chr7: 149714695-149715338;

S1PR1, chr1: 101236505-101237190;

PPP1R16B, chr20: 38805341-38807221;

IKZF1, chr7: 50304053-50304994;

LONRF2, chr2: 100322082-100322599;

ZFP82, chr19: 36418330-36418931;

FLT3, chr13: 28099881-28100943;

FBN1, chr15: 48644595-48646444; and

FLI1, chr11: 128693042-128694372.

9. The method of claim 1 , wherein the pre-determined methylation signature panel comprises twelve or more genomic regions selected from the group consisting of

ITGA4, chr2: 181457004-181457950;

EMBP1, chr1: 121519076-121519744;

TMEM163, chr2: 134718243-134719428;

SFMBT2, chr10: 7408046-7408953;

ELMO1, chr7: 37448612-37449471;

ZNF543, chr19: 57320164-57320845;

SFMBT2, chr10: 7410025-7411008;

CHST10, chr2: 100417269-100417795;

ELMO1, chr7: 37447852-37448217;

CCNA1, chr13: 36431498-36432414;

BEND4, chr4: 42150707-42153216;

KRBA1, chr7: 149714695-149715338;

S1PR1, chr1: 101236505-101237190;

PPP1R16B, chr20: 38805341-38807221;

IKZF1, chr7: 50304053-50304994;

LONRF2, chr2: 100322082-100322599;

ZFP82, chr19: 36418330-36418931;

FLT3, chr13: 28099881-28100943;

FBN1, chr15: 48644595-48646444; and

FLI1, chr11: 128693042-128694372.

10. The method of claim 1 , wherein the colorectal cancer is selected from the group consisting of stage 1 colorectal cancer, stage 2 colorectal cancer, stage 3 colorectal cancer, and stage 4 colorectal cancer.

11. The method of claim 1 , wherein the pre-determined methylation signature panel comprises a genomic region selected from the group consisting of:

IKZF1; chr: 50304053-50304944;

ELMO1; chr7: 37448612-37449471; and

ELMO; chr7: 37447852-37448217.

12. The method of claim 1 , wherein the pre-determined methylation signature panel comprises a genomic region selected from the group consisting of:

IKZF1; chr: 50304053-50304944;

ELMO1; chr7: 37448612-37449471;

ELMO; chr7: 37447852-37448217; and

FLI1; chr11: 128693042-128694372.

13. The method of claim 1 , further comprising performing a colonoscopy on the subject after (e) to treat the colorectal cancer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2023
From: ST. JOHN, JOHN; KOTHEN-HILL, STEVEN; YANG, RUI; DRAKE, ADAM
To: FREENOME HOLDINGS, INC.
Reel/Frame 065500/0686 →
Continuity (4)
Continuation 17954576 · Sep 28, 2022
Continuation PCTUS2021024604 · Mar 29, 2021
Provisional Application 63002878 · Mar 31, 2020
Related Publication 20230220492A1 · Jul 13, 2023
References Cited (94)
US 5786146A · Herman et al. · 1998 [cited by applicant]
US 7270960B2 · Hellstrom et al. · 2007 [cited by applicant]
US 7727720B2 · Dhallan · 2010 [cited by applicant]
US 7754429B2 · Rigatti et al. · 2010 [cited by applicant]
US 8168385B2 · Brenner · 2012 [cited by applicant]
US 8318433B2 · Brenner · 2012 [cited by applicant]
US 9040239B1 · Zheng et al. · 2015 [cited by applicant]
US 9080210B2 · Van Eijk et al. · 2015 [cited by applicant]
US 9447452B2 · Rao et al. · 2016 [cited by applicant]
US 10337053B2 · Rao et al. · 2019 [cited by applicant]
US 10443091B2 · Rao et al. · 2019 [cited by applicant]
US 10533213B2 · Rao et al. · 2020 [cited by applicant]
US 10731204B2 · Rao et al. · 2020 [cited by applicant]
US 10767216B2 · Rao et al. · 2020 [cited by applicant]
US 10774373B2 · Rao et al. · 2020 [cited by applicant]
US 10978175B2 · Van Eijk et al. · 2021 [cited by applicant]
US 11072818B2 · Rao et al. · 2021 [cited by applicant]
US 11208683B2 · Rao et al. · 2021 [cited by applicant]
US 11514289B1 · Otte et al. · 2022 [cited by applicant]
US 11681953B2 · Drake et al. · 2023 [cited by applicant]
US 11781959B2 · Delubac · 2023 [cited by applicant]
US 11847532B2 · Drake et al. · 2023 [cited by applicant]
US 20080194413A1 · Albert · 2008 [cited by applicant]
US 20080194414A1 · Albert et al. · 2008 [cited by applicant]
US 20090221438A1 · Kitzman et al. · 2009 [cited by applicant]
US 20100131286A1 · Houlgatte et al. · 2010 [cited by applicant]
US 20100151471A1 · Faham et al. · 2010 [cited by applicant]
US 20130022974A1 · Chinnaiyan et al. · 2013 [cited by applicant]
US 20140365243A1 · Varadan et al. · 2014 [cited by applicant]
US 20160040246A1 · Ahlquist et al. · 2016 [cited by applicant]
US 20170277844A1 · Apte et al. · 2017 [cited by applicant]
US 20180102187A1 · Apte et al. · 2018 [cited by applicant]
US 20180119137A1 · Matsuguchi et al. · 2018 [cited by applicant]
US 20200232894A1 · Delubac · 2020 [cited by applicant]
US 20210010076A1 · Delubac et al. · 2021 [cited by applicant]
US 20210057046A1 · Liu et al. · 2021 [cited by applicant]
US 20210174958A1 · Drake et al. · 2021 [cited by applicant]
US 20210210205A1 · Drake et al. · 2021 [cited by applicant]
US 20210230684A1 · Ariazi et al. · 2021 [cited by applicant]
US 20210272653A1 · Ulz et al. · 2021 [cited by applicant]
US 20230101485A1 · St. John et al. · 2023 [cited by applicant]
US 20230220492A1 · St. John et al. · 2023 [cited by applicant]
CN 105143465A · 2015 [cited by applicant]
EP 3152333B1 · 2019 [cited by applicant]
WO WO2016115530A1 · 2016 [cited by applicant]
WO WO2016119190A1 · 2016 [cited by applicant]
WO WO2019060716A1 · 2019 [cited by applicant]
WO WO2019071161A1 · 2019 [cited by applicant]
WO WO2019100024A1 · 2019 [cited by applicant]
WO WO2019147663A1 · 2019 [cited by applicant]
WO WO2019191649A1 · 2019 [cited by applicant]
WO WO2019195268A2 · 2019 [cited by applicant]
WO WO2019200410A1 · 2019 [cited by applicant]
WO WO2020076772A1 · 2020 [cited by applicant]
WO WO2020243609A1 · 2020 [cited by applicant]
WO WO2021202351A1 · 2021 [cited by applicant]
WO WO2021222220A2 · 2021 [cited by applicant]
WO WO2022076237A1 · 2022 [cited by applicant]
WO WO2022140116A1 · 2022 [cited by applicant]
WO WO2022204358A1 · 2022 [cited by applicant]
WO WO2022261192A1 · 2022 [cited by applicant]
WO WO2023003851A1 · 2023 [cited by applicant]
WO WO2023147472A1 · 2023 [cited by applicant]
WO WO2023183468A2 · 2023 [cited by applicant]
WO WO2023235878A2 · 2023 [cited by applicant]
WO WO2023244983A1 · 2023 [cited by applicant]
WO WO2023250441A2 · 2023 [cited by applicant]
Li et al. (Clinical Chemistry (2019) vol. 65:7; pp. 916-926). [cited by examiner]
Prescott et al. (PLoS Genetics (2014) vol. 11:19 pages). [cited by examiner]
Klett et al. (Epigenetics (2018) vol. 13:386-397). [cited by examiner]
Yagi et al. [Clin. Cancer Res., 16(1); 21-33; 2010]. [cited by examiner]
Li et al. (Bioinformatics (2002) vol. 18(11) 1427-1431). [cited by examiner]
Asmus et al. Simultaneous Targeted Methylation Sequencing (sTM-Seq). Curr Protoc Hum Genet 101(1):e81, pp. 1-19 doi:10.1002/cphg.81 (2019). [cited by applicant]
Booth et al. Quantitative Sequencing of 5-Methylcytosine and 5-Hydroxymethylcytosine at Single-Base Resolution. Science 336(6083):934-937 (2012). [cited by applicant]
Fay et al. Confidence intervals of the Mann-Whitney parameter that are compatible with the Wilcoxon-Mann-Whitney test. Stat Med 37(27):3991-4006 doi:10.1002/sim.7890 (2018). [cited by applicant]
Friedland et al. Development and Clinical Validation of a blood test for early detection of colorectal adenomas and cancer. Abstract 32305, Poster ASCO GI Meeting [1-1] (2021). [cited by applicant]
Frommer et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. PNAS USA 89:1827-1831 (1992). [cited by applicant]
Geneva: World Health Organization: WHO list of priority medical devices for cancer management, WHO Medical device technical series. ISBN: 978-92-4-156546-2, License: CC BY-NC-SA 3.0 IGO, pp. 1-252 (2017). [cited by applicant]
Golub et al. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring, Science, American Association for the Advancement of Science, 286:5439 (Oct. 15, 1999), pp. 531-537. [cited by applicant]
Herman, J.G., et al. Methylation-Specific PCR: A Novel PCR Assay for Methylation Status of CpG Islands. Proceedings of the National Academy of Science USA 93:9821-9826, Sep. 1996. [cited by applicant]
Kourou et al. Machine learning applications in cancer prognosis and prediction. Comput Struct Biotechnol J.13:8-17 (2014). [cited by applicant]
Liu et al. An individualized predictor of health and disease using paired reference and target samples. BMC Bioinformatics 17:47 [1-15] (2016). [cited by applicant]
Liu et al. Bisulfite-Free Direct Detection of 5-Methylcytosine and 5-Hydroxymethylcytosine at Base Resolution. Nature Biotechnology 37(4):424-429 (2019). [cited by applicant]
Manghnani et al. METCC: METric learning for Confounder Control Making distance matter in high dimensional biological analysis. arXiv:1812.03188v1 [cs.LG] [1-10] (2018), 10 pages. [cited by applicant]
PCT/US2021/024604 International Search Report and Written Opinion dated Jul. 13, 2021. [cited by applicant]
Schutsky et al. Nondestructive, Base-Resolution Sequencing of 5-Hydroxymethylcytosine Using a DNA Deaminase. Nature Biotechnology 36(11):1083-1090 (2018). [cited by applicant]
Singh, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell. vol. 1, pp. 203-209 (2002). [cited by applicant]
Wan et al. Machine learning enables detection of early-stage colorectal cancer by whole-genome sequencing of plasma cell-free DNA. bioRxiv prePrint URL:https://doi.org/10.1101/478065 [1-22] (2018). [cited by applicant]
Wolpin et al. Systemic treatment of colorectal cancer. Gastroenterology 134(5):1296-1310 doi:10.1053/j.gastro.2008.02.098 (2008). [cited by applicant]
Yu et al. Tet-assisted bisulfite sequencing of 5-hydroxymethylcytosine. Nat Protoc. 7(12):2159-2170 doi:10.1038/nprot.2012.137 (2012). [cited by applicant]
Zhang et al. Tet-mediated covalent labelling of 5-methylcytosine for its genome-wide detection and sequencing, Nat Commun. 2013;4:1517, 10 pages. [cited by applicant]
CN202180039398.8 Office Action with Search Report dated Oct. 25, 2024, and a partial English translation. [cited by applicant]
PCT/US2022/024604 International Preliminary Report on Patentability dated Sep. 29, 2022. [cited by applicant]
EP21780407.9 Extended European Search Report dated Jun. 6, 2024. [cited by applicant]